首页> 外文期刊>The annals of pharmacotherapy >Use of oral vitamin K for prevention of late vitamin K deficiency bleeding in neonates when injectable vitamin K is not available [Uso profiláctico de vitamina K oral para la hemorragia por deficiencia de vitamina K tardía en neonatos cuando la vitamina K inyectable no está disponible]
【24h】

Use of oral vitamin K for prevention of late vitamin K deficiency bleeding in neonates when injectable vitamin K is not available [Uso profiláctico de vitamina K oral para la hemorragia por deficiencia de vitamina K tardía en neonatos cuando la vitamina K inyectable no está disponible]

机译:当无法使用注射用维生素K时,口服维生素K可以预防新生儿晚期维生素K缺乏症出血[无法使用注射式维生素K时预防性使用新生婴儿的口服维生素K可预防新生儿晚期维生素K缺乏性出血]

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: To evaluate the literature describing use of oral vitamin K1 (phytonadione) to prevent late vitamin K deficiency bleeding (VKDB) in neonates when injectable vitamin K preparations are not available. DATA SOURCES: Articles were retrieved through MEDLINE (1946-February 2012) using the terms vitamin K, vitamin K deficiency bleeding, newborn, neonate, and prophylaxis. Reference citations from publications identified were reviewed. STUDY SELECTION AND DATA EXTRACTION: All articles published in English on the use of prophylactic oral vitamin K in neonates were evaluated. The largest epidemiologic studies discussing the efficacy of continuous oral vitamin K prophylaxis were reviewed. Individual, smaller clinical trials were not reviewed. DATA SYNTHESIS: For prevention of early, classic, and late VKDB, use of intramuscular vitamin K 1 mg is preferred over oral administration because of superior efficacy. Single oral doses protect against early VKDB, but multiple oral doses are needed for late VKDB prophylaxis, especially in exclusively breast-fed neonates. Continuous oral dosing regimens used in the literature vary; European epidemiologic data suggest the lowest rates of late VKDB with oral vitamin K 1 mg at birth followed by 25 μg daily for 13 weeks, or 2 mg at birth followed by 1 mg weekly for 3 months. Limited data describe the use of oral prophylactic vitamin K in high-risk patients (eg, premature neonates, biliary abnormalities). CONCLUSIONS: While there are data supporting effective oral vitamin K dosing regimens for prevention of late VKBD in exclusively breast-fed neonates, lack of an appropriate oral dosage form prevents routine use of this technique in the US. In times of drug shortage, injectable vitamin K preparations should be reserved for use in neonates. If injectable vitamin K is not available, clinicians should choose the most practical method of administering oral vitamin K based on the oral products available.
机译:目的:评估没有口服维生素K制剂时使用口服维生素K1(植酮二酮)预防新生儿晚期维生素K缺乏性出血(VKDB)的文献。数据来源:通过MEDLINE(1946-2012年2月)使用维生素K,维生素K缺乏性出血,新生儿,新生儿和预防用语检索文章。对已鉴定出版物的参考文献进行了审查。研究选择和数据提取:评价了所有以英语发表的有关预防性口服维生素K在新生儿中的使用的文章。讨论了最大的流行病学研究,这些研究讨论了持续口服维生素K预防的功效。个别较小的临床试验未审查。数据合成:为了预防早期,经典和晚期VKDB,由于其优越的疗效,与口服给药相比,肌内维生素K 1 mg的使用更为可取。单次口服可预防早期VKDB,但晚期VKDB预防需要多次口服,特别是在纯母乳喂养的新生儿中。文献中使用的连续口服给药方案有所不同。欧洲流行病学数据表明,出生后口服维生素K的晚期VKDB发生率最低,出生后每天25 mg,持续13周;出生时每天2 mg,随后三个月,每周1 mg。有限的数据描述了在高危患者(例如,早产儿,胆道异常)中使用口服预防性维生素K。结论:虽然有数据支持仅口服母乳喂养的新生儿预防晚期VKBD的有效口服维生素K给药方案,但缺乏合适的口服剂型在美国无法常规使用该技术。在药物短缺时,应保留可注射的维生素K制剂供新生儿使用。如果没有可注射的维生素K,临床医生应根据现有的口服产品选择最实用的口服维生素K给药方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号